The groundbreaking rise of Viagra has long been a benchmark of pharmaceutical success, yet its position within the broader market now raises questions about potential gains. Alternative versions are undercutting market share, prompting worries that investing in companies significantly dependent to Viagra's once-dominant standing could be a problema